Daiichi/Sankyo Merger Leaves Future Of OTC Unit Up In The Air
This article was originally published in The Pink Sheet Daily
Executive Summary
The combined firms’ nonprescription and other non-core businesses could become independent subsidiaries or a separate company, Daiichi CEO says. Daiichi Sankyo may follow the lead of Chugai, which divested its OTC business in 2004.
You may also be interested in...
Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.
P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.
USP Advisory Group To Evaluate International Harmonization Efforts
A committee comprising stakeholders will discuss ways of improving USP's work with international pharmacopeias to harmonize excipient monographs and general chapters.